Press Enter to search · ESC to close

US Stocks

BeiGene to Invest $19.5M in Bravera Series A

BeiGene announced that its wholly owned subsidiary BeiGene Switzerland will invest $19.5 million in cash in Bravera Bio’s Series A round alongside affiliate Baker Bros entities and other investors, and will convert $500,000 of SAFE interests into Series A preferred shares. Upon completion, BeiGene Switzerland will hold 9.477% of Bravera. The transaction is a related-party deal but not a major asset restructuring, and requires no board or shareholder approval.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback